Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A

Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A

Phosphoproteomics is a promising tool for identifying biomarkers of treatment response in cancer. Here, the authors analyse proteomics profiling of HER2-negative female breast cancer patients and identify potential predictors of paclitaxel response.

Bibliographic Details
Main Authors: S. Mouron, M. J. Bueno, A. Lluch, L. Manso, I. Calvo, J. Cortes, J. A. Garcia-Saenz, M. Gil-Gil, N. Martinez-Janez, J. V. Apala, E. Caleiras, Pilar Ximénez-Embún, J. Muñoz, L. Gonzalez-Cortijo, R. Murillo, R. Sánchez-Bayona, J. M. Cejalvo, G. Gómez-López, C. Fustero-Torre, S. Sabroso-Lasa, N. Malats, M. Martinez, A. Moreno, D. Megias, M. Malumbres, R. Colomer, M. Quintela-Fandino
Format: Article
Language:English
Published: Nature Portfolio 2022-12-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-022-35065-z

Internet

https://doi.org/10.1038/s41467-022-35065-z

Similar Items